Cover Image
市場調查報告書

主要已開發國家的慢性阻塞性肺病(COPD)治療藥的市場

COPD Therapeutics in Major Developed Markets to 2021 - Emergence of Addition-in-Class and First-in-Class Products Offsets Sales Erosion of Leading Brands

出版商 GBI Research 商品編碼 347858
出版日期 內容資訊 英文 122 Pages
訂單完成後即時交付
價格
Back to Top
主要已開發國家的慢性阻塞性肺病(COPD)治療藥的市場 COPD Therapeutics in Major Developed Markets to 2021 - Emergence of Addition-in-Class and First-in-Class Products Offsets Sales Erosion of Leading Brands
出版日期: 2015年11月13日 內容資訊: 英文 122 Pages
簡介

所謂慢性阻塞性肺病(COPD),是呼吸道和肺的慢性發炎發病這樣的進行性疾病。特徵是持續性呼吸困難,以及症狀相繼惡化、復發,佔全球第5大死因。慢性阻塞性肺病的風險要素有很多,不過,抽煙為主要原因,以及環境污染物質也有影響。目前已上市產品,以藥理性方法管理慢性阻塞性肺病相關症狀為主體,不過,還沒開發出緩和疾病的長期進展的治療藥。現在,203種產品在臨床實驗中,不過,部分包含應該稱為First-in-Class (劃時代的新產品)的東西,瞭解到對這個疾病的作用機制的理解加深了。

本報告提供全球主要已開發國家(美國、英國、法國、德國、義大利、西班牙、日本、加拿大)的慢性阻塞性肺病 (以下慢性阻塞性肺病) 的治療藥的市場相關分析、疾病概要和目前主要治療方法、現在已上市、臨床實驗中主要的治療藥的概要與臨床實驗的進展、全球及各國的市場趨勢預測(今後7年份)、主要的推動及阻礙市場要素、市場最新趨勢(資本交易、共同開發等)、今後的市場方向性等調查。

第1章 目錄

第2章 簡介

  • 疾病的概要
  • 症狀
  • 病因
  • 病理生理學
  • 診斷
  • 疾病的重病度的評估法
  • 治療方法
  • 治療流程
    • 輕症的慢性阻塞性肺病
    • 中∼重症的慢性阻塞性肺病
    • 極重症的慢性阻塞性肺病
    • 已上市產品的熱圖

第3章 已上市產品

  • 產品簡介
    • 支氣管擴張藥和吸入式皮質類固醇的聯合治療
    • 支氣管擴張藥的單劑療法
    • 支氣管擴張藥的聯合治療
    • 替代療法
    • 結論
    • 未滿足需求

第4章 慢性阻塞性肺病的開發中產品

  • 分子標的分析
  • 臨床實驗
    • 失敗率
    • 臨床實驗的有效期
    • 臨床實驗的規模
    • 臨床實驗的各種指標比較分析
  • 有前途的開發平台分子
    • Mepolizumab - GSK
    • Vilanterol Trifenatate - GSK/Theravance
    • Fluticasone Furoate + Umeclidinium Bromide + Vilanterol Trifenatate - GSK
    • Budesonide + Formoterol Fumarate + Glycopyrronium (PT010) - AstraZeneca/Pearl Therapeutics
    • Glycopyrronium + Formoterol Fumarate (PT003) - AstraZeneca/Pearl Therapeutics
    • Glycopyrronium + Formoterol Fumarate 預測
    • Benralizumab - AstraZeneca/MedImmune
    • TD-4208 - Theravance
    • Beclomethasone Dipropionate + Formoterol Fumarate + Glycopyrronium - Chiesi Farmaceutici
    • 開發中產品的熱圖

第5章 到市場預測 (2021年)

  • 全球市場
  • 北美
    • 治療方法的使用模式
    • 年度治療費用
    • 市場規模
  • 歐洲主要5個國家
  • 日本
  • 慢性阻塞性肺病市場促進&阻礙因素
    • 推動市場要素
    • 市場阻礙因素

第6章 資本交易及策略性產業重組

  • 授權合約 (共5件)
  • 共同開發契約 (共5件)

第7章 附錄

  • 所有開發平台醫藥品:各Phase
    • 藥物研發
    • 臨床實驗前
    • 第一階段
    • 第二階段
    • 第三階段
    • 登記完畢
  • 市場預測 (到2021年)
    • 全球
    • 美國
    • 加拿大
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 日本
  • 參考文件
  • 簡稱集
  • 分析方法
  • 關於專家小組
  • 諮詢方式
  • 免責聲明

圖表一覽

目錄
Product Code: GBIHC374MR

Executive Summary

Chronic Obstructive Pulmonary Disease (COPD) is a progressive disorder associated with chronic inflammation of the airways and lungs. Persistent breathing difficulties and repeated exacerbations of COPD symptoms make the disease one of the leading causes of morbidity, and the fifth-leading cause of death in the world. COPD is linked to cumulative exposure to risk factors, primarily tobacco smoke, but also environmental pollutants. The COPD marketed products landscape consists of pharmacological therapies aimed at managing the symptoms associated with COPD, although none of the available therapies have been shown to modify long-term disease progression.

There are currently 203 products in active development, excluding four with an unknown stage of development. Although many of the targets identified in the pipeline are well established in the management of COPD, there are some novel, first-in-class targets. This reflects the growing understanding of the underlying mechanisms that characterize the disease.

Scope

The COPD market has benefited from notable additions over recent years.

Which classes of drug dominate the market?

What additional benefits have newly approved therapies brought to market?

How do the leading marketed therapies compare clinically?

The pipeline contains a range of molecule types and molecular targets, including those that are well established in COPD, and novel, first-in-class therapies.

Which molecular targets appear most frequently in the pipeline?

How will the new therapies be positioned in the treatment of COPD?

How have selected late-stage pipeline therapies performed in clinical trials?

COPD clinical trials have an overall attrition rate of 89.6%.

What are the failure rates for individual Phases of clinical development?

How do COPD clinical trial characteristics, including failure rate, duration, and size compare against respiratory and industry averages?

The COPD market is forecast to rise from a value of $9.2 billion in 2014 to $11.2 billion in 2021, at a CAGR of 2.9% across the eight major markets assessed.

How much of a role will disease prevalence and new product approvals play in market growth?

Will generic competition have a significant impact on the market over the forecast period?

There have been 59 licensing deals and 41 co-development deals pertaining to COPD products since 2006.

Which territories show the most deal activity?

What were the trends in deal completion by product stage of development?

What were the conditions of the key licensing or co-development deals to take place in COPD?

Reasons to buy

  • This report will allow you to -
  • Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment algorithm used in COPD.
  • Assess the safety and efficacy of current treatment options, with extensive product profiles on prominent marketed therapies, and a heatmap directly comparing safety and efficacy data.
  • Analyze the COPD pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.
  • Predict growth in market size in eight major markets, with in-depth market forecasting from 2014 to 2021. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
  • Identify commercial opportunities in the COPD deals landscape by analyzing trends in licensing and co-development deals, and by profiling the most significant deals that have occurred in this indication in recent years.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Introduction
  • 2.2. Symptoms
  • 2.3. Etiology
  • 2.4. Pathophysiology
  • 2.5. Diagnosis
  • 2.6. Assessment of Disease Severity
  • 2.7. Treatment
  • 2.8. Treatment Algorithm
    • 2.8.1. Mild COPD
    • 2.8.2. Moderate-to-Severe COPD
    • 2.8.3. Very Severe COPD
    • 2.8.4. Marketed Products Heat Map

3. Marketed Products

  • 3.1. Product Profiles
    • 3.1.1. Bronchodilator and Inhaled Corticosteroid Combination Therapy
    • 3.1.2. Bronchodilator Monotherapy
    • 3.1.3. Bronchodilator Combination Therapy
    • 3.1.4. Alternative Therapy
    • 3.1.5. Conclusion
    • 3.1.6. Unmet Needs

4. COPD Pipeline

  • 4.1. Molecular Target Analysis
  • 4.2. Clinical Trials
    • 4.2.1. Failure Rate
    • 4.2.2. Clinical Trial Duration
    • 4.2.3. Clinical Trial Size
    • 4.2.4. Comparative Clinical Trial Metrics Analysis
  • 4.3. Promising Pipeline Molecules
    • 4.3.1. Mepolizumab - GSK
    • 4.3.2. Vilanterol Trifenatate - GSK/Theravance
    • 4.3.3. Fluticasone Furoate + Umeclidinium Bromide + Vilanterol Trifenatate - GSK
    • 4.3.4. Budesonide + Formoterol Fumarate + Glycopyrronium (PT010) - AstraZeneca/Pearl Therapeutics
    • 4.3.5. Glycopyrronium + Formoterol Fumarate (PT003) - AstraZeneca/Pearl Therapeutics
    • 4.3.6. Glycopyrronium + Formoterol Fumarate Forecast
    • 4.3.7. Benralizumab - AstraZeneca/MedImmune
    • 4.3.8. TD-4208-Theravance
    • 4.3.9. Beclomethasone Dipropionate + Formoterol Fumarate + Glycopyrronium - Chiesi Farmaceutici
    • 4.3.10. Heat Map for Pipeline Products

5. Market Forecast to 2021

  • 5.1. Global Market
  • 5.2. North America
    • 5.2.1. Treatment Usage Patterns
    • 5.2.2. Annual Cost of Therapy
    • 5.2.3. Market Size
  • 5.3. Top Five EU Markets
    • 5.3.1. Treatment Usage Patterns
    • 5.3.2. Annual Cost of Therapy
    • 5.3.3. Market Size
  • 5.4. Japan
    • 5.4.1. Treatment Usage Patterns
    • 5.4.2. Annual Cost of Therapy
    • 5.4.3. Market Size
  • 5.5. Drivers and Barriers for the COPD market
    • 5.5.1. Drivers
    • 5.5.2. Barriers

6. Deals and Strategic Consolidations

  • 6.1. Licensing Deals
    • 6.1.1. AstraZeneca Enters into Licensing Agreement with Synairgen for SNG001
    • 6.1.2. Evotec Enters into Licensing Agreement with Zhejiang Conba for EVT 401
    • 6.1.3. Vectura Enters into Licensing Agreement with International Pharma Company for VR315
    • 6.1.4. Almirall Enters into Licensing Agreement with Kyorin for Aclidinium Bromide
    • 6.1.5. Pulmagen Therapeutics Enters into Research and Licensing Agreement with AstraZeneca
  • 6.2. Co-development Deals
    • 6.2.1. Theravance Enters into Development and Commercialization Agreement with Mylan
    • 6.2.2. Five Prime Therapeutics Expands Co-Development Agreement with GSK
    • 6.2.3. Galapagos Enters into Strategic Alliance with Roche
    • 6.2.4. Forest Laboratories Enters into Agreement with Almirall
    • 6.2.5. Forest Laboratories Enters into Co-Development Agreement with Nycomed

7. Appendix

  • 7.1. All Pipeline Drugs by Phase
    • 7.1.1. Discovery
    • 7.1.2. Preclinical
    • 7.1.3. Phase I
    • 7.1.4. Phase II
    • 7.1.5. Phase III
    • 7.1.6. Filed
  • 7.2. Market Forecasts to 2021
    • 7.2.1. Global
    • 7.2.2. US
    • 7.2.3. Canada
    • 7.2.4. UK
    • 7.2.5. France
    • 7.2.6. Germany
    • 7.2.7. Italy
    • 7.2.8. Spain
    • 7.2.9. Japan
  • 7.3. Bibiography
  • 7.4. Abbreviations
  • 7.5. Research Methodology
    • 7.5.1. Secondary Research
    • 7.5.2. Marketed Product Profiles
    • 7.5.3. Late-Stage Pipeline Candidates
    • 7.5.4. Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
    • 7.5.5. Forecasting Model
    • 7.5.6. Deals Data Analysis
  • 7.6. Expert Panel Validation
  • 7.7. Contact Us
  • 7.8. Disclaimer

List of Tables

  • Table 1: COPD Market, Disease Severity, 2015
  • Table 2: COPD Market, Patient Risk Categories, 2015
  • Table 3: COPD Market, Treatment Algorithm, 2015
  • Table 4: COPD Market, Global, Pipeline Products, Discovery, 2015
  • Table 5: COPD Market, Global, Pipeline Products, Preclinical, 2015
  • Table 6: COPD Market, Global, Pipeline Products, Phase I, 2015
  • Table 7: COPD Market, Global, Pipeline Products, Phase II, 2015
  • Table 8: COPD Market, Global, Pipeline Products, Phase III, 2015
  • Table 9: COPD Market, Global, Pipeline Products, Filed, 2015
  • Table 10: COPD Market, Global, Market Forecast, 2014-2021
  • Table 11: COPD Market, US, Market Forecast, 2014-2021
  • Table 12: COPD Market, Canada, Market Forecast, 2014-2021
  • Table 13: COPD Market, UK, Market Forecast, 2014-2021
  • Table 14: COPD Market, France, Market Forecast, 2014-2021
  • Table 15: COPD Market, Germany, Market Forecast, 2014-2021
  • Table 16: COPD Market, Italy, Market Forecast, 2014-2021
  • Table 17: COPD Market, Spain, Market Forecast, 2014-2021
  • Table 18: COPD Market, Japan, Market Forecast, 2014-2021

List of Figures

  • Figure 1: COPD Market, Global, Marketed Products Heat Map, Moderate to Severe, Efficacy, 2015
  • Figure 2: COPD Market, Global, Marketed Products Heat Map, Moderate to Severe, Safety, 2015
  • Figure 3: COPD Market, Global, Marketed Products Heat Map, Very Severe, Efficacy, 2015
  • Figure 4: COPD Market, Global, Marketed Products Heat Map, Very Severe, Safety, 2015
  • Figure 5: COPD Market, Global, Pipeline, 2015
  • Figure 6: COPD Market, Global, Pipeline, Molecular Target, 2015
  • Figure 7: COPD Market, Global, Pipeline, Molecular Target Tier 2 , 2015
  • Figure 8: COPD Market, Global, Clinical Trial Failure Rate, 2015
  • Figure 9: COPD Market, Global, Clinical Trial Failure Rate by Molecular Target, 2015
  • Figure 10: COPD Market, Global, Clinical Trial Duration by Stage of Development, 2015
  • Figure 11: COPD Market, Global, Clinical Trial Duration by Stage of Development and Molecule Target, 2006-2015
  • Figure 12: COPD Market, Global, Clinical Trial Size by Product, 2015
  • Figure 13: COPD Market, Global, Clinical Trial Size by Individual Clinical Trial, 2015
  • Figure 14: COPD Market, Global, Clinical Trial Size by Individual Clinical Trial, 2015
  • Figure 15: COPD Market, Global, Clinical Trial Size by Individual Clinical Trial, 2015
  • Figure 16: COPD Market, Global, Comparison by Average Trial Metrics by Phase and Molecular Target, 2015
  • Figure 17: COPD Market, Global, Mepolizumab Market Forecast, 2017-2021
  • Figure 18: COPD Market, Global, Vilanterol Trifenatate Market Forecast, 2017-2021
  • Figure 19: COPD Market, Global, Fluticasone Furoate + Umeclidinium Bromide + Vilanterol Trifenatate Market Forecast, 2017-2021
  • Figure 20: COPD Market, Global, Budesonide + Formoterol Fumarate + Glycopyrronium Market Forecast, 2018-2021
  • Figure 21: COPD Market, Global, Glycopyrronium + Formoterol Fumarate Market Forecast, 2016-2021
  • Figure 22: COPD Market, Global, Benralizumab Forecast, 2018-2021
  • Figure 23: COPD Market, Global, TD-4208 Forecast, 2017-2021
  • Figure 24: COPD Market, Global, Beclomethasone Dipropionate + Formoterol Fumarate + Glycopyrronium Forecast, 2018-2021
  • Figure 25: COPD Market, Global, Pipeline Heat map, Efficacy, 2015
  • Figure 26: COPD Market, Global, Pipeline Heat map, Safety, 2015
  • Figure 27: COPD Market, Global, Treatment Patterns, Market Size, 2014-2021
  • Figure 28: COPD Market, North America, Treatment Usage Patterns, 2014-2021
  • Figure 29: COPD Market, North America, Annual Cost of Therapy ($), 2014-2021
  • Figure 30: COPD Market, North America, Market Size, 2014-2021
  • Figure 31: COPD Market, Top Five EU Markets, Treatment Usage Patterns, 2014-2021
  • Figure 32: COPD Market, Top Five EU Markets, Annual Cost of Therapy, 2014-2021
  • Figure 33: COPD Market, Top Five EU Markets, Market Size, 2014-2021
  • Figure 34: COPD Market, Japan, Treatment Usage Patterns, 2014-2021
  • Figure 35: COPD Market, Japan, Annual Cost of Therapy, 2014-2021
  • Figure 36: COPD Market, Japan, Market Size, 2014-2021
  • Figure 37: COPD Market, Global, Licensing Deals by Region, 2006-2015
  • Figure 38: COPD Market, Global, Licensing Deals by Value, 2006-2015
  • Figure 39: COPD Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006-2015
  • Figure 40: COPD Market, Global, Licensing Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2015
  • Figure 41: COPD Market, Global, Licensing Deals by Molecule Type, Stage of Development and Aggregate Deal Value ($m), 2006-2015
  • Figure 42: COPD Market, Global, Licensing Deals by Mechanism of Action and Aggregate Deal Value ($m), 2006-2015
  • Figure 43: COPD Market, Global, Co-development Deals by Region, 2006-2015
  • Figure 44: COPD Market, Global, Co-development Deals by Value, 2006-2015
  • Figure 45: COPD Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Value ($m), 2006-2015
  • Figure 46: COPD Market, Global, Co-development Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2015
  • Figure 47: COPD Market, Global, Co-development Deals by Molecule Type, Stage of Development and Aggregate Deal Value ($m), 2006-2015
  • Figure 48: COPD Market, Global, Co-development Deals by Mechanism of Action and Aggregate Deal Value ($m), 2006-2015
Back to Top